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Available online 1 September 2015Regular aspirin use reduces colon adenoma and carcinoma incidence. UDP-glucuronosyltransferases (UGT) are
involved in aspirin metabolism and clearance, and variant alleles in UGT1A6 have been shown to alter salicylic
acid metabolism and risk of colon neoplasia. In a randomized, cross-over, placebo-controlled trial of 44 healthy
men and women, homozygous for UGT1A6*1 or UGT1A6*2, we explored differences between global epithelial
and stromal expression, usingAffymetrixU133+2.0microarrays and tested effects of 60-day aspirin supplemen-
tation (325 mg/d) on epithelial and stromal gene expression and colon prostaglandin E2 (PGE2) levels. We con-
ducted a comprehensive study of differential gene expression between normal human colonic epithelium and
stroma from healthy individuals. Although no statistically signiﬁcant differences in gene expression were ob-
served in response to aspirin or UGT1A6 genotype, we have identiﬁed the genes uniquely and reproducibly
expressed in each tissue type and have analyzed the biologic processes they represent. Herewe describe in detail
how the data, deposited in the Gene Expression Omnibus (GEO) – accession number GSE71571 –was generated
including the basic analysis as contained in the manuscript published in BMC Medical Genetics with the PMID
25927723 (Thomas et al., 2015 [9]).
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).(Speciﬁcationsrganism/cell
line/tissueHomo sapiens/colon/epithelial and stromal tissuex Males and femalesC
quencer or
array typeAffymetrix GeneChip HGU133+2.0 microarraysata format Raw and normalized
xperimental
factorsSaWe tested effects of 60-day aspirin supplementation (325
mg/d) on epithelial and stromal gene expression in 44 healthy
men and women who were randomly assigned, blocked on sex
and genotype, to the order in which they received treatment A
or treatment B. (Note: The type of treatment i.e., pill type
active or placebo was masked).xperimental
featuresThe washout period between intervention periods was three
months. A sigmoidoscopy was performed at least 60 days after
day 1 of each intervention period. Therefore, two biopsies
were obtained from each participant and then processed,).
. This is an open access article under thcontinued)
Speciﬁcationse CC BY license (httwhere by, epithelial and stromal fractions were separated and
analyzed using Affymetrix U133+2.0 microarrays. This re-
sulted in obtaining total RNA from 88 epithelial and 88
matched stromal samples. A total of 176 gene arrays were run.onsent All study procedures and materials were approved by the Fred
Hutchinson Cancer Research Center Human Research
Protection Program, Institutional Review Board Committee C
and informed, written consent was obtained from all partici-
pants prior to their starting the study.mple source
locationStudy participants were recruited from the greater Seattle, WA
area between June 2003 and March 20071. Direct link to deposited data
The direct link to deposited ﬁles is at http://datalink.elsevier.com/
midas/datalink/api/downloadﬁles?items=17107-17108-17109.
The direct link to deposited genomic data is at http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE71571.p://creativecommons.org/licenses/by/4.0/).
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The objectives of this study were to measure effects of an aspirin in-
tervention on gene expression in normal colonic epithelial and stromal
tissue in healthy humans and to determine whether response differed
byUGT1A6*2 genotype.We also sought to characterize gene expression
differences within colonic tissue microenvironments by identifying
genes that were differentially expressed between epithelial and stromal
tissue.2.1. Participants
We recruited healthymen andwomen, ages 20 to 45 years, from the
greater Seattle area between June 2003 and March 2007. Participants
were recruited from among those who completed a cross-sectional
study of diet and aspirin metabolism (Fig. 1). Potential eligibility was
assessed by questionnaire. Exclusion criteria included tobacco use, con-
sumption of N2 alcoholic beverages/day (equivalent to 720 ml beer,
240 ml wine, 90 ml hard liquor), regular use of prescription or over-
the-counter medications, known intolerance of aspirin or other non-
steroidal anti-inﬂammatory drugs (NSAID), weight loss or gain of
N4.5 kg in the past year, current or planned pregnancy, breastfeeding,
bleeding disorder, anemia, renal insufﬁciency, hepatic dysfunction
(e.g., cirrhosis, hepatitis, abnormal liver function tests), chronic lung
disease, hypertension, congestive heart failure, angina, recent myocar-
dial infarction, history of endocarditis, aortic or iliac aneurysm, history
of stroke or transient ischemic attack, diabetes, recent pelvic surgery,
history of gastrointestinal disorder (e.g., gastric or duodenal ulcer, ulcer-
ative colitis, Crohn's disease, celiac sprue, HNPCC, familial adenomatous
polyposis, pancreatic disease, previous gastrointestinal resection, radia-
tion or chemotherapy) and cancer (other than non-melanoma skin
cancer).Fig. 1. Flow chart of participant enrollment and study design.As part of the cross-sectional study, participants completed a self-
administered food frequency questionnaire and a health and demo-
graphic survey, and provided a fasting morning blood that was used
for UGT1A6 genotyping [1]. We determined the UGT1A6*2 genotype
of 434 participants by Sanger sequencing of a 268 bp fragment of exon
1, ampliﬁed by PCR as described previously [2].
2.2. Study design
The study was a randomized, double-blind crossover clinical trial de-
signed to examine the effects of aspirin on gene expression in colonic
mucosa. Our goal was to have at least 40 participants complete both
arms of the trial. Participantswere selected on the basis of their genotype
of rs2070959 (T181A) and rs1105879 (R184S) — 20 with the UGT1A6
*1/*1 genotype (homozygous for the major allele at both SNPs) and 20
with the UGT1A6 *2/*2 genotype (homozygous for the minor allele at
both SNPs). All participants with a *2/*2 genotype and sex-matched par-
ticipants with a *1/*1 genotype were invited to consider participation in
the trial. Fifty-ﬁve individuals (23men), mean (SD) age 30.1 (6.5) years,
were randomized. Ten participants discontinued the study: 3 did not tol-
erate the Fleets Phospho-soda preparation prior to the ﬁrst sigmoidosco-
py, 2 started on prescriptionmedications, 2 refused sigmoidoscopy, 3 left
for reasons unrelated to the study and sufﬁcient total RNA could not be
extracted from one participant. Forty-two participants were included in
the analysis of intervention and UGT1A6 genotype effects and an addi-
tional 3 participants with the UGT1A6 *2/*4 genotype were randomized
and included in the expression array analysis of stromal and epithelial
tissue. (Initially, we randomized *2/*4 individuals into the study because
the phenotype was thought to be similar to that of *2/*2; however, with
the emergence of newdata [10], we decided that the 2 genotypesmay be
sufﬁciently different and therefore excluded *2/*4 individuals from the
intervention analysis.)
To ensure that participants could take aspirin safely for 60 days and
tolerate sigmoidoscopy, each participant underwent a clinical assess-
ment before entering the study that included a detailedmedical history,
measurement of blood pressure and complete blood count, liver panel,
chemistry panel, blood urea nitrogen, serum creatinine, urinalysis, and
in women only, a pregnancy test. In addition, a physician interviewed
and examined participants before each of their sigmoidoscopies. The
laboratory assays to assess the health of participants were completed
by a commercial lab (CLIA licensed Quest Diagnostics, Seattle, WA).
Because this was a randomized crossover trial, each person served as
his/her own control, receiving both intervention (aspirin) and control
(placebo) at 2 different periods, with awashout period between periods.
Participants were randomly assigned, blocked on sex and genotype, to
the order in which they received aspirin or placebo. Eligible participants
took 325 mg aspirin or a visually identical placebo by mouth daily, for
60 days. The washout period between intervention periods was 3
months. A sigmoidoscopy was performed at least 60 days after day 1 of
each intervention period. Participants took the study medication up
until 24 h before their sigmoidoscopies. During each treatment period,
we monitored adherence to the study medication by pill count.
2.3. Sigmoidoscopy, biopsy collection, and tissue separation
Participants prepared for sigmoidoscopy by following standard in-
structions for use of Fleet Phospho-soda Oral Saline Laxative (Lynch-
burg, VA), which included adherence to a clear-liquid diet for 24 h
before the procedure. At each sigmoidoscopy, we used large-cup ﬂexi-
ble biopsy forceps (Precisor Disposable, Bard, Billerica, MA) to obtain bi-
opsies of normal-appearing mucosa from the sigmoid colon. Forty-ﬁve
participants completed both sigmoidoscopies. Within 1 min of removal
from the colon, three biopsies were transferred to Hank's buffer con-
taining 20 mM EDTA and 40 mM dithiothreitol at 4 °C and were held
on ice for 10–15 min. The epithelial cells were separated from the stro-
mal layer by vortexing [3]. The stromal layer was removed with an
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trifugation. Both fractions were frozen and stored in liquid nitrogen
until RNA extraction.2.4. RNA extraction and microarray procedures
Participants were labeled consecutively. There are 4 samples from
each person designated A1–A4 (participant 1); A5–A6 (participant 2);
B1–B4 (participant 3) etc. to W1–W4 (participant 44). Within the data
for each person, odd numbers (1 and 3) are epithelial tissue and even
numbers (2 and 4) are stromal tissue. The epithelial and stroma from
each intervention period are paired together (e.g., A1 and A2 are from
the ﬁrst treatment Participant 1 received; A3 and A4 are from the sec-
ond treatment participant 1 received). Each participant's epithelial
and stromal samples were processed at the same time. Total RNA was
extracted with RNeasy extraction kits (Qiagen, Valencia, California)
and treated with DNAse I according to the manufacturer's protocol.
The integrity of total RNA samples was veriﬁed by visual analysis of
18S and 28S bands on an ethidium bromide-stained 1.5% agarose gel.
RNA was quantiﬁed using the Quant-iT RiboGreen RNA assay Kit (Mo-
lecular Probes, Eugene, Oregon). We obtained sufﬁcient RNA from 44
of the 45 participants. This resulted in obtaining total RNA from 88 epi-
thelial samples and 88matched stromal samples. cRNAwas synthesized
from 100 ng of total RNA, biotin-labeled by the GeneChip Two-cycle
cDNA synthesis labeling protocol (Affymetrix, Inc., Santa Clara, Califor-
nia), and then hybridized to HGU133 plus 2.0 expression arrays.Fig. 2. Real-time PCR conﬁrms differences in gene expression in colonic epithelium and strom
from 10 study participants for four candidate genes. The histogram bars from the same indiv
taken at two separate visits. Total RNA was reverse transcribed and then ampliﬁed by PCR and
stromal tissue. Upper panel shows expression of: (i) ABCC3, an epithelial gene involved in drug
binding and protein transport. Lower panel shows expression of: (iii) ANXA1 (annexin A1), a
stromal gene involved in extracellular matrix formation.GeneChips were washed and stained in the Affymetrix Fluidics Station
450. GeneChips were scanned using the GeneChip Scanner 3000 7G.
Each microarray contained 54,675 probes representing 38,500 genes.
The quality control (QC) criteria used to assess sample and chip perfor-
mance were fold-ampliﬁcation after two cycles of in vitro transcription
(to be at least 40-fold), and increasing signal strengths and ‘present’
calls for poly-A RNA spike-in controls (lys, phe, thr, dap) and hybridiza-
tion controls (bioB, bioC, bioD and cre). Microarray data are publicly
available in Gene Expression Omnibus (GEO) with the accession num-
ber GSE71571.2.5. Real-time quantitative reverse transcription-polymerase chain reaction
(qRT-PCR)
To validate themicroarray data, TaqManRT-PCRwas performed on a
total of 20 RNA samples, which included both pairs of stromal and epi-
thelial samples from 10 of the 44 individuals. To ensure an RT perfor-
mance of equal quality, all samples were reverse transcribed
simultaneously by a two-step reverse transcription with SuperScript
RT II (Invitrogen, Carlsbad, California). Relative gene expressionwas ex-
amined by TaqMan PCR using 2×TaqMan Gene Expression Master Mix
(Applied Biosystems, Foster City, California) and TaqMan Gene Expres-
sion Assays for two epithelial genes (ABCC3, MLPH; assay identiﬁers
Hs00358677_m1 and Hs00983106_m1) and two stromal genes
(ITGα8 and ANXA1; assay identiﬁers Hs00943530_m1 and
Hs00945401_m1). Human β-glucuronidase (GUSB) was used as thea. Quantitative real-time RT-PCR was done on both biopsies (taken at two separate visits)
idual are located next to each other, i.e., samples 1 and 2 are from the same person but
normalized to β-glucuronidase (GUSB) expression. Blue bars: epithelial tissue. Red bars:
and lipidmetabolism; and (ii)MLPH (melanophilin), an epithelial gene involved in protein
stromal gene involved in cell migration and cell adhesion; and (iv) ITGA8 (integrin α8), a
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ples in the microarray analysis. Relative quantiﬁcation was performed
with the ABI Prism 7900 HT sequence detection system and calculated
by the comparative CT method.
2.6. PGE2 analysis
PGE2 inwhole biopsies collected at the end of each treatment period
was measured with enzyme immunoassay kits from Assay Design
(Farmingdale, NY). Brieﬂy, each frozen biopsy tissue sample was trans-
ferred to a sealedmicrocentrifuge tube towhich 500 μl of ice-cold tissue
homogenization buffer had been added previously [4]. Each samplewas
homogenized by an Ultrasonic Processor (Misonix, Farmingdale, NJ) at
4 °C for 3.5 min × 2 with a 1-min rest in between and then centrifuged
at 16,000 rpm for 5 min at 4 °C. An aliquot (100 μl) was mixed with
100 μl of assay buffer and acidiﬁedwith 20 μl 1 N citric acid. The acidiﬁed
solution was then applied to a Sep.-Pak C18 cartridge (Waters Corp.,
Milford, MA) that had been preconditioned with methanol and water.
Prostaglandins were eluted with 2 ml of hexane:ethyl acetate (1:1).
The eluate was evaporated under a stream of nitrogen, and the residue
was dissolved in 25 μl ethanol and 200 μl assay buffer. PGE2 was then
measured with ELISA kits according to the manufacturer's instructions.
Protein levels were determined by a Bradford protein assay (Bio-Rad,
Hercules, CA). Levels of PGE2 were normalized to protein concentra-
tions and expressed as ng/mg protein.
2.7. Data analysis–microarray analysis
Data were normalized by the Robust Multi-array Analysis with cor-
rection for GC content of the oligo (GC-RMA) [5]. Subsequently, the
probe-set expression levels were log2-transformed using GC-RMA (ver-
sion 2.40.0) and R version 3.2.1 (2015–06–18) with default function set-
tings. Nonspeciﬁc ﬁltering was done where estimated intensities were
required to be above 100ﬂuorescence units in at least 25% of the samplesTable 1
Statistically signiﬁcant pathways and functions in colonic epithelium and stroma.
Epithelial genes
Canonical pathways p-Value
Xenobiotic metabolism signaling 0.000124
Fatty acid metabolism 0.00262
Apoptosis signaling 0.22
Biological function
Epithelial genes p-value 6.25E-07-2.47E-02
Small molecule biochemistry 6.25E-07-2.47E-02
Molecular transport 5.89E-05-2.47E-02
Carbohydrate metabolism 7.48E-04-2.47E-02
Drug metabolism 1.80E-03-2.47E-02
Protein trafﬁcking 2.34E-03-2.47E-02
Nucleic acid metabolism 8.58E-03-2.47E-02
Amino acid metabolism 1.23E-02-2.47E-02
Stromal genes
Canonical pathways p-Value
Complement system 2.49E-08
Antigen presentation pathway 0.00000018
IL-4 signaling 0.0000656
Biological function
Inﬂammation 8.74E-28-8.17E-06
Cell-to-cell signaling 1.90E-27-1.09E-05
Immunological disease 5.34E-25-4.44E-06
Hematological system development & function 4.50E-19-1.12E-05
Immune response 4.50E-19-1.12E-05
Ingenuity PathwayAnalysis of selected biological functional groups andmetabolic and sig-
nalingpathways for all statistically signiﬁcant genes of both tissue types. Range of p-values
indicates the signiﬁcance values of the speciﬁc sub-functions associated with that partic-
ular high-level function. Italic font indicates that function was unique to that particular tissue
type and was essentially not expressed in the other tissue.and the interquartile range (IQR) across all of the samples on the log base
2 scale was expected to be at least 0.6. A total of 6227 genes passed non-
speciﬁc ﬁltering. Differential expression between tissue types in biopsies
collected at the end of each treatment period was determined by using a
paired t-test. The false discovery rate (FDR)was calculated using the pro-
cedure proposed by Benjamini andHochberg [6]. Visualization of the sta-
tistically signiﬁcant genes was performed in GeneSpring 7.0 with per
chip and per gene normalizations (Agilent Technologies, Wilmington,
Delaware). Ingenuity Pathways Analysis (IPA, Release Summer 2013)
(Ingenuity Systems, Redwood City, California, www.ingenuity.com)
was used to determine the relevant functions and pathways expressed
in each tissue type. A list of the top genes in each pathwaywas identiﬁed
using GeneSpring and heat maps for each pathway were generated by
clustering these genes in Gene Cluster 3.0 [7] and then visualizing the
clusters using Java TreeView [8]. Differential expression between inter-
ventions within each tissue type and between two UGT1A6 genotypes
(*1/*1 and *2/*2) were also examined by using the same paired t-test
and the generalized estimating equation approach. Genes that were sta-
tistically signiﬁcantly differentially expressed between stroma and epi-
thelium at the end of both treatment periods were included in further
pathway analysis.
2.8. Data analysis–PGE2 analysis
Because the distributions of PGE2 levels measured in biopsies col-
lected at the end of each treatment period were skewed, the data
were logarithmically transformed. The difference between treatments
was determined by using paired t-test and a random-effects model
that takes into account the crossover design. The comparison between
aspirin and placebo was further examined after stratiﬁcation for sex,
age, and UGT1A6 genotypes.
3. Results
Tissue-speciﬁc patterns of gene expression in epithelium and stroma
of normal human colon. From 38,500 genes analyzed bymicroarray, we
identiﬁed genes that were statistically signiﬁcantly differentially
expressed between epithelium and stroma in each treatment period.
Because there were no intervention differences, we combined the ob-
servations and restricted subsequent analyses to those genes that
were differentially expressed in both treatment periods (P b 0.01,
FDR b 0.001). This resulted in further exploration of 4916 genes. Of
these, 2088 were higher in stroma and 2828 were higher in epithelium.
Stromal and epithelial patterns of expression observed in themicro-
array data were conﬁrmed by qRT-PCR of selected genes (Fig. 2). Ex-
pression of the selected epithelial-speciﬁc genes, ABCC3 and MLPH1,
was detectable in the stromal samples, but at a lower level than in the
epithelial samples. In contrast, the selected stromal-speciﬁc genes,
ANXA1 and ITGA8, generally lacked detectable expression in the epithe-
lial samples.
To understand the biologic processes represented by differentially
expressed genes,we analyzed those showing statistically signiﬁcant dif-
ferences with Ingenuity Pathways Analysis (IPA). Although both com-
partments expressed genes involved with cancer, cell death, cell
signaling and cellular movement, several pathways and biologic func-
tions appeared to be unique to one or the other tissue. Table 1 lists the
major differentially expressed pathways and functions by tissue type.
4. Conclusion
We have identiﬁed the genes uniquely and reproducibly expressed
in each tissue type and have analyzed the biologic processes they
represent. The wide differences in expression between stroma and
epithelium suggest that future study of gene expression in colonic
epithelium may beneﬁt from separation of the tissue so as to focus the
analysis on a speciﬁc tissue type.
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